Bénédicte Lefebvre, Yu Kang, Azin Vakilpour, Takeshi Onoue, Noelle V Frey, Priya Brahmbhatt, Brian Huang, Kemi Oladuja, Daniel Koropeckyj-Cox, Courteney Wiredu, Amanda M Smith, Jesse Chittams, Joseph Carver, Marielle Scherrer-Crosbie
BACKGROUND: Previous retrospective studies have shown that chimeric antigen receptor T (CAR-T) cell therapy may be associated with major adverse cardiovascular events (MACE), especially in the context of cytokine-release syndrome (CRS) events. OBJECTIVES: The aim of this prospective observational study was to define the occurrence of MACE in adults undergoing treatment with CAR-T cell therapy and identify associated risk factors. METHODS: Vital signs, blood samples, and an echocardiogram were collected prior to and 2 days, 1 week, 1 month, and 6 months after CAR-T cell infusion, and charts were consulted at 12 months...
December 2023: JACC CardioOncology